Extension Study of Participants From SPG302-ALZ-101
NCT06833281
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
12
Enrollment
INDUSTRY
Sponsor class
Stopped
patients treated on compassionate use program
Conditions
Alzheimer's Disease
Interventions
DRUG:
SPG302
Sponsor
Spinogenix